Galectin Therapeutics Inc (NASDAQ:GALT) shares, rose in value on Wednesday, June 18, with the stock price up by 37.66% to the previous day’s close as strong demand from buyers drove the stock to $3.29.
Actively observing the price movement in the last trading, the stock closed the session at $2.39, falling within a range of $2.3152 and $3.3. The value of beta (5-year monthly) was 0.545. Referring to stock’s 52-week performance, its high was $3.17, and the low was $0.73. On the whole, GALT has fluctuated by 147.37% over the past month.
With the market capitalization of Galectin Therapeutics Inc currently standing at about $208.23 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-15.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that GALT’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of GALT currently trading nearly 124.34% and 136.25% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 92.90, while the 7-day volatility ratio is showing 20.92% which for the 30-day chart, stands at 12.48%. Furthermore, Galectin Therapeutics Inc (GALT)’s beta value is 0.54, and its average true range (ATR) is 0.25.
A comparison of Galectin Therapeutics Inc (GALT) with its peers suggests the former has fared considerably weaker in the market. GALT showed an intraday change of 37.66% in last session, and over the past year, it grew by 25.57%%.
Data on historical trading for Galectin Therapeutics Inc (NASDAQ:GALT) indicates that the trading volumes over the past 10 days have averaged 1.88 and over the past 3 months, they’ve averaged 387.78K. According to company’s latest data on outstanding shares, there are 63.29 million shares outstanding.
Nearly 31.40% of Galectin Therapeutics Inc’s shares belong to company insiders and institutional investors own 15.75% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 8.9 million shares as on 2025-05-30, resulting in a short ratio of 52.08. According to the data, the short interest in Galectin Therapeutics Inc (GALT) stood at 2360.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 8.47 million. The stock has risen by 155.04% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the GALT stock heading into the next quarter.
